Olistic Women finished product · Six-month TrichoScan hair density — Evidence Check

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Comparative efficacy: finished product and selected endpointWhat are the selected finished-product question and original subclaim assessment?Required	The selected row concerns increased six-month TrichoScan hair density with this finished product, original grade C and a note of day-180 +27.31 versus +18.23 hairs/cm². The parent is C with 50 points. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Original six-month TrichoScan hair-density text, grade and note	Distinguish the original assessment from production and review of existing content
2	Partly verified	Full text not readStored summary read	N02 · Comparative efficacy: finished product and selected endpointWhat are the actual population and scope of telogen-effluvium diagnosis?Required	CT-OW-02 allocated 106 premenopausal women diagnosed with telogen effluvium, 53 per group. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Premenopausal women, diagnosis, eligibility, baseline and exclusions	Distinguish the recruited population from other hair-loss conditions and populations
3	Partly verified	Full text not readStored summary read	N03 · Comparative efficacy: finished product and selected endpointWhat are the actual finished product and study exposure?Required	Exposure to one 25-mL vial/day of the Olistic Women drinkable multi-ingredient nutraceutical for six months is recorded. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Olistic Women finished product, formulation, study exposure and duration	Distinguish finished-product identity from actual exposure and guidance
4	Partly verified	Full text not readStored summary read	N04 · Comparative efficacy: finished product and selected endpointAre placebo composition, appearance and blinding verified?Required	The trial was multicenter, double-blind and placebo-controlled; the company supplied product and placebo. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Product/placebo composition, matching and blinding implementation	Distinguish the design name from actual blinding implementation
5	Partly verified	Full text not readStored summary read	N05 · Comparative efficacy: finished product and selected endpointAre allocation, analysis, completion and missing-data denominators separated?Required	The original evidence lists 106 randomized (53/53). R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	106 allocated, 53/53, measurements/analysis/exclusions by timepoint	Separate allocation from actually observed and analyzed denominators
6	Partly verified	Full text not readStored summary read	N06 · Comparative efficacy: finished product and selected endpointWhat is the original record scope for random-sequence generation and allocation concealment?Required	The preserved research explanation says random-sequence generation and allocation-concealment methods were not confirmed in the public paper. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Sequence, concealment, baseline, actual implementation and original descriptions	Distinguish historically unverified methods from current summary reading
7	Partly verified	Full text not readStored summary read	N07 · Comparative efficacy: finished product and selected endpointAre missing-data handling, analysis populations and effects of interest known?Required	The original summary says detailed missing-data handling was not confirmed in the public paper. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Group exclusions, missingness, ITT/PP, models and adjustment	Separate allocation, actual use, completers and missing-data assumptions
8	Unverified	Full text not readStored summary read	N08 · Comparative efficacy: finished product and selected endpointCan concurrent treatment, changes in hair-loss causes and product adherence be distinguished?Required	The current preserved summary gives a finished-product/placebo comparison and six months. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Concurrent treatment, nutrition, other products, causes, changes and adherence	Distinguish finished-product effects from other possible changes
9	Partly verified	Full text not readStored summary read	N09 · Comparative efficacy: finished product and selected endpointWhat are the primary endpoint’s measurement, unit and definition?Required	The primary endpoint was change from baseline in hair density measured by TrichoScan phototrichoscopy. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	TrichoScan phototrichoscopy, change from baseline in density and hairs/cm²	Distinguish device-measured density from patient-centered outcomes
10	Partly verified	Full text not readStored summary read	N10 · Comparative efficacy: finished product and selected endpointDo day-180 changes by group differ from final density?Required	Day-180 change is recorded as product +27.31±2.61 versus placebo +18.23±2.98 hairs/cm². R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Baseline, change and final values for each group and definition of ±	Distinguish changes, absolute values, dispersion and precision
11	Partly verified	Full text not readStored summary read	N11 · Comparative efficacy: finished product and selected endpointWhat are the test and confidence interval for the selected between-group comparison?Required	The preserved summary gives P<0.01 for the day-180 hair-density comparison and says the 95% CI was not reported. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Day-180 comparison, effect scale, P value and CI	Display directly reported tests together with gaps in effects/CIs
12	Partly verified	Full text not readStored summary read	N12 · Comparative efficacy: finished product and selected endpointDoes an important clinical difference explain the device measurement?Required	The preserved counterview says a clinically important minimum hairs/cm² threshold was not reported. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Prespecified hairs/cm² importance, direct perception and clinical criteria	Separate statistical values from clinical importance
13	Partly verified	Full text not readStored summary read	N13 · Comparative efficacy: finished product and selected endpointWas the day-90 result counted as independent replication or merged with day 180?Required	The original description says between-group differences occurred at both days 90 and 180. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Values, denominators, plans and measurements by timepoint	Distinguish direct timepoint data from shared participants and measurements
14	Partly verified	Full text not readStored summary read	N14 · Comparative efficacy: finished product and selected endpointWas the secondary hair-cycle ratio merged with density?Required	The original text gives a prespecified secondary ratio of product 8.20:1→14.19:1 versus placebo 7.43:1→8.76:1, P<0.001. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Anagen-to-catagen/telogen ratio, hierarchy and definition	Distinguish density, hair-cycle ratios and analysis hierarchy
15	Partly verified	Full text not readStored summary read	N15 · Comparative efficacy: finished product and selected endpointAre first registration posting and primary-completion dates distinguished?Required	NCT07111312 was first posted on 2025-08-08; primary completion was 2024-05-10. The original text describes retrospective registration after completion, which cannot support prospective registration. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	NCT07111312, first posting, completion, original plans and history	Display completion, registration and paper events separately
16	Partly verified	Full text not readStored summary read	N16 · Comparative efficacy: finished product and selected endpointDo original primary/secondary descriptions differ from independently prespecified plans?Required	The preserved summary calls density primary and the hair-cycle ratio a prespecified secondary endpoint while also stating limits of retrospective registration. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Endpoint hierarchy, protocol/SAP, multiplicity and change documents	Distinguish paper hierarchy descriptions from the verified scope of independent prospective plans
17	Partly verified	Full text not readStored summary read	N17 · Comparative efficacy: finished product and selected endpointDoes TrichoScan density mean visibly fuller hair?Required	The original text distinguishes TrichoScan hair counts from a patient judging hair to look fuller. The separate appearance subclaim has grade ?. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Direct appearance, satisfaction, perception and function endpoints	Distinguish device measurements from gaps in the separate appearance question
18	Partly verified	Full text not readStored summary read	N18 · Comparative efficacy: finished product and selected endpointWas a finished-product effect extended to ingredients or other hair supplements?Required	The original advertising interpretation says ingredients, formulations and populations vary by product, so Olistic results cannot become effects of Viviscal, Nutrafol or all hair supplements. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Direct comparisons for this product, other formulations and individual ingredients	Preserve applicability boundaries between this product and other product/ingredient questions
19	Unverified	Full text not readStored summary read	N19 · Comparative efficacy: finished product and selected endpointDoes six-month efficacy mean persistence after completion or prevention of all hair loss?Required	The original trial lasted six months/180 days; the original counterpoint says it does not establish durability or effects of other formulations. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Postcompletion follow-up, long-term density and clinical outcomes	Distinguish exposure-period results from direct postcompletion results
20	Partly verified	Full text not readStored summary read	N20 · Comparative efficacy: finished product and selected endpointAre the same trial, citation, registration and two subclaims independent replication?Required	The original material links one trial in 106 people, one citation and NCT07111312. Density, hair-cycle ratios, days 90/180 and the appearance sibling row share the same report context. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	CT-OW-02, paper, registration, shared participants and timepoint linkage	Distinguish endpoint/report slots from trial/participant units
21	Partly verified	Full text not readStored summary read	N21 · Comparative efficacy: finished product and selected endpointIs there independent replication beyond one small manufacturer trial?Required	The original rationale describes one trial in 106 people (53/53), the limitation of fewer than 200 participants and manufacturer-only evidence. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Actual independent replication of the same finished product, population and duration	Distinguish original sample-size limits from gaps in independent replication
22	Partly verified	Full text not readStored summary read	N22 · Comparative efficacy: finished product and selected endpointAre research funding, publication fees and product/placebo support separated?Required	The original text says Olistic Research Labs S.L. fully funded research and publication fees and supplied product and placebo. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Company funding, publication fees and product/placebo supply disclosures	Display research costs, publication fees and product support separately
23	Partly verified	Full text not readStored summary read	N23 · Comparative efficacy: finished product and selected endpointAre sponsor, responsible party and company-employed author distinguished?Required	The original text says the company was sponsor/responsible party and Manuel Sáez Moya was affiliated with the company. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Responsibility, registrant, author relationships/contributions and data rights	Distinguish support, responsibility, employees and individual roles
24	Unverified	Full text not readStored summary read	N24 · Comparative efficacy: finished product and selected endpointWere all outsourced analysis, medical writing and editing roles verified?Required	Research/publication costs, product/placebo supply and some responsibility/affiliation information are preserved. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Actual disclosures of analysis, writing, editing and other support	Record reported involvement separately from unverified roles
25	Partly verified	Full text not readStored summary read	N25 · Supplementary harm evidenceAre noncollection and nonreporting of minor adverse events distinguished?Supplementary	The original research explanation and safety detail explicitly say minor adverse events were not collected at all. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Harm collection/classification, group observations and exposure denominators	Distinguish noncollection from observed zero events and nonreporting
26	Unverified	Full text not readStored summary read	N26 · Supplementary harm evidenceAre serious-harm, discontinuation and relatedness material available?Supplementary	The summary explicitly states minor adverse events were not collected and this trial alone cannot establish safety. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Serious events, discontinuation/reasons, relatedness, control and denominators	Display collection limits separately from gaps in other harm material
27	Unverified	Full text not readStored summary read	N27 · Supplementary harm evidenceCan long-term/rare harms or tolerability in other populations be judged?Supplementary	The original trial lasted six months and harm collection was incomplete. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Long exposure, rare events, vulnerable populations and follow-up	Distinguish short-term efficacy values from gaps in long-term safety
28	Partly verified	Full text not readStored summary read	N28 · Comparative efficacy: finished product and selected endpointAre the actually read summary and external abstract/full text/registration/plans shown?Required	The full preserved summary was actually read; the PubMed URL is linked as an original bibliographic reference. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Preserved summary, citation URL and actual reading status by material	Display summary reading and unread external material separately
29	Partly verified	Full text not readStored summary read	N29 · Comparative efficacy: finished product and selected endpointAre original history, parent values and linkage separated from production and review of existing content?Required	Preserve Korean/English text, axes, the 2026-08-26 evidence date, empty correction/deliberation records and subclaims in the full original summary. Existing review-pending/production-eligibility indicators are historical. R01	Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment	Korean/English text, axes, dates, corrections, existing selection and freeze/application	Record original assessment/corrections separately from production and review of existing content

No items match your search or filter.

29 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: 106 premenopausal women diagnosed with telogen effluvium allocated (53/53); analyzed, measured and completed denominators by timepoint are unverified
Ingredient, formulation and route: Olistic Women finished drinkable multi-ingredient nutraceutical
Dose: Original study exposure: one 25-mL vial/day for six months; not intake guidance or product recommendations
Comparator: Trial placebo; detailed composition and blinding specifications unread
Measured outcome: Change from baseline to day 180 in TrichoScan hair density, hairs/cm²; distinct from appearance, perception and hair-cycle ratios
Duration: Six months/180 days; the day-90 repeat timepoint is a separate result, and persistence after completion is unverified
Questions outside this scope: No new research, effects, CIs, calculations, assessments, independent certification, participant totals or product/drug-use/dosing/treatment or adjunct-treatment reduction/discontinuation guidance is created

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

R01 · Sáez Moya M, et al. Efficacy and Safety of a Drinkable Nutraceutical in Premenopausal Women with Telogen Effluvium. Dermatol Ther (Heidelb). 2025. PMID: 41288927.

PubMed

Material type: Preserved summary of trial-paper bibliography
Materials actually read: Summary read; external abstracts, full texts, registration and plans unread
Findings recorded in the stored summary: +27.31±2.61 versus +18.23±2.98 hairs/cm², P<0.01; 95% CI not reported
Record level: Six-month TrichoScan hair density with the CT-OW-02 finished product; distinct from appearance, long-term outcomes and other products
Study overlap and independent replication: Two groups, days 90/180, endpoints, registration and sibling rows of one CT-OW-02; do not sum as independent replication

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Summary read	Stored summary read	Summary read	Material slot; no certification of external acquisition/reading/link checks or independent-trial counts
External abstract	Not read	External material unread	Not read	Material slot; no certification of external acquisition/reading/link checks or independent-trial counts
External full text	Not read	External material unread	Not read	Material slot; no certification of external acquisition/reading/link checks or independent-trial counts
Original registration	Not read	External material unread	Not read	Material slot; no certification of external acquisition/reading/link checks or independent-trial counts
Protocol/SAP	Not read	External material unread	Not read	Material slot; no certification of external acquisition/reading/link checks or independent-trial counts

Report counts versus independent study counts

Two groups, days 90/180, endpoints, registration and sibling rows of one CT-OW-02; do not sum as independent replication

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · What are the selected finished-product question and original subclaim assessment?

Required materials and conditions: Original six-month TrichoScan hair-density text, grade and note
Conditions for verification: Original six-month TrichoScan hair-density text, grade and note; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N02 · What are the actual population and scope of telogen-effluvium diagnosis?

Required materials and conditions: Premenopausal women, diagnosis, eligibility, baseline and exclusions
Conditions for verification: Premenopausal women, diagnosis, eligibility, baseline and exclusions; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N03 · What are the actual finished product and study exposure?

Required materials and conditions: Olistic Women finished product, formulation, study exposure and duration
Conditions for verification: Olistic Women finished product, formulation, study exposure and duration; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N04 · Are placebo composition, appearance and blinding verified?

Required materials and conditions: Product/placebo composition, matching and blinding implementation
Conditions for verification: Product/placebo composition, matching and blinding implementation; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N05 · Are allocation, analysis, completion and missing-data denominators separated?

Required materials and conditions: 106 allocated, 53/53, measurements/analysis/exclusions by timepoint
Conditions for verification: 106 allocated, 53/53, measurements/analysis/exclusions by timepoint; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N06 · What is the original record scope for random-sequence generation and allocation concealment?

Required materials and conditions: Sequence, concealment, baseline, actual implementation and original descriptions
Conditions for verification: Sequence, concealment, baseline, actual implementation and original descriptions; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N07 · Are missing-data handling, analysis populations and effects of interest known?

Required materials and conditions: Group exclusions, missingness, ITT/PP, models and adjustment
Conditions for verification: Group exclusions, missingness, ITT/PP, models and adjustment; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N08 · Can concurrent treatment, changes in hair-loss causes and product adherence be distinguished?

Required materials and conditions: Concurrent treatment, nutrition, other products, causes, changes and adherence
Conditions for verification: Concurrent treatment, nutrition, other products, causes, changes and adherence; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N09 · What are the primary endpoint’s measurement, unit and definition?

Required materials and conditions: TrichoScan phototrichoscopy, change from baseline in density and hairs/cm²
Conditions for verification: TrichoScan phototrichoscopy, change from baseline in density and hairs/cm²; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N10 · Do day-180 changes by group differ from final density?

Required materials and conditions: Baseline, change and final values for each group and definition of ±
Conditions for verification: Baseline, change and final values for each group and definition of ±; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N11 · What are the test and confidence interval for the selected between-group comparison?

Required materials and conditions: Day-180 comparison, effect scale, P value and CI
Conditions for verification: Day-180 comparison, effect scale, P value and CI; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N12 · Does an important clinical difference explain the device measurement?

Required materials and conditions: Prespecified hairs/cm² importance, direct perception and clinical criteria
Conditions for verification: Prespecified hairs/cm² importance, direct perception and clinical criteria; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N13 · Was the day-90 result counted as independent replication or merged with day 180?

Required materials and conditions: Values, denominators, plans and measurements by timepoint
Conditions for verification: Values, denominators, plans and measurements by timepoint; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N14 · Was the secondary hair-cycle ratio merged with density?

Required materials and conditions: Anagen-to-catagen/telogen ratio, hierarchy and definition
Conditions for verification: Anagen-to-catagen/telogen ratio, hierarchy and definition; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N15 · Are first registration posting and primary-completion dates distinguished?

Required materials and conditions: NCT07111312, first posting, completion, original plans and history
Conditions for verification: NCT07111312, first posting, completion, original plans and history; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N16 · Do original primary/secondary descriptions differ from independently prespecified plans?

Required materials and conditions: Endpoint hierarchy, protocol/SAP, multiplicity and change documents
Conditions for verification: Endpoint hierarchy, protocol/SAP, multiplicity and change documents; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N17 · Does TrichoScan density mean visibly fuller hair?

Required materials and conditions: Direct appearance, satisfaction, perception and function endpoints
Conditions for verification: Direct appearance, satisfaction, perception and function endpoints; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N18 · Was a finished-product effect extended to ingredients or other hair supplements?

Required materials and conditions: Direct comparisons for this product, other formulations and individual ingredients
Conditions for verification: Direct comparisons for this product, other formulations and individual ingredients; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N19 · Does six-month efficacy mean persistence after completion or prevention of all hair loss?

Required materials and conditions: Postcompletion follow-up, long-term density and clinical outcomes
Conditions for verification: Postcompletion follow-up, long-term density and clinical outcomes; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N20 · Are the same trial, citation, registration and two subclaims independent replication?

Required materials and conditions: CT-OW-02, paper, registration, shared participants and timepoint linkage
Conditions for verification: CT-OW-02, paper, registration, shared participants and timepoint linkage; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N21 · Is there independent replication beyond one small manufacturer trial?

Required materials and conditions: Actual independent replication of the same finished product, population and duration
Conditions for verification: Actual independent replication of the same finished product, population and duration; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N22 · Are research funding, publication fees and product/placebo support separated?

Required materials and conditions: Company funding, publication fees and product/placebo supply disclosures
Conditions for verification: Company funding, publication fees and product/placebo supply disclosures; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N23 · Are sponsor, responsible party and company-employed author distinguished?

Required materials and conditions: Responsibility, registrant, author relationships/contributions and data rights
Conditions for verification: Responsibility, registrant, author relationships/contributions and data rights; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N24 · Were all outsourced analysis, medical writing and editing roles verified?

Required materials and conditions: Actual disclosures of analysis, writing, editing and other support
Conditions for verification: Actual disclosures of analysis, writing, editing and other support; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N25 · Are noncollection and nonreporting of minor adverse events distinguished?

Required materials and conditions: Harm collection/classification, group observations and exposure denominators
Conditions for verification: Harm collection/classification, group observations and exposure denominators; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Supplementary
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N26 · Are serious-harm, discontinuation and relatedness material available?

Required materials and conditions: Serious events, discontinuation/reasons, relatedness, control and denominators
Conditions for verification: Serious events, discontinuation/reasons, relatedness, control and denominators; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Supplementary
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N27 · Can long-term/rare harms or tolerability in other populations be judged?

Required materials and conditions: Long exposure, rare events, vulnerable populations and follow-up
Conditions for verification: Long exposure, rare events, vulnerable populations and follow-up; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Supplementary
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N28 · Are the actually read summary and external abstract/full text/registration/plans shown?

Required materials and conditions: Preserved summary, citation URL and actual reading status by material
Conditions for verification: Preserved summary, citation URL and actual reading status by material; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

N29 · Are original history, parent values and linkage separated from production and review of existing content?

Required materials and conditions: Korean/English text, axes, dates, corrections, existing selection and freeze/application
Conditions for verification: Korean/English text, axes, dates, corrections, existing selection and freeze/application; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Requirement and applicability: Required
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved methodological linkages reused for production; no current methodological reassessment or external link checks, and historical quality review is not inherited

What the statuses mean

Partly verified: Some information exists in the preserved review summary; detailed original materials remain unverified. This does not certify a passed review or clinical efficacy.
Unverified: Detailed materials for the selected condition could not be established within the stored scope; this does not mean zero effect, zero studies or safety
Review incomplete: Review of existing content incomplete
Met: Use only within the relevant conditions after existing content review; no automatic designation in this preparation
Not reported: Distinguish only within materials actually read; do not turn unread external materials into unreported findings
Inaccessible: Not applied during this preparation because actual access was not tested
Not applicable: Use with a reason for non-applicability based on an explicit question boundary
Conflicting data: Judge after actual material comparison; review was not performed during this preparation
Insufficient evidence for the conditions: Do not use as a clinical grade encompassing currently unread materials

Change history

2026-10-12 · Public page/material version 1.0

Public pages and materials were created from the existing 29 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · What are the selected finished-product question and original subclaim assessment?

Current findings: The selected row concerns increased six-month TrichoScan hair density with this finished product, original grade C and a note of day-180 +27.31 versus +18.23 hairs/cm². The parent is C with 50 points.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: The selected row has no score, status or axes. Do not fill subclaim scores/axes from parent values or create a new assessment.
Required materials and conditions: Original six-month TrichoScan hair-density text, grade and note
Materials to obtain first: Selected row and original parent assessment
Further research: Distinguish the original assessment from production and review of existing content
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Original six-month TrichoScan hair-density text, grade and note; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N02 · What are the actual population and scope of telogen-effluvium diagnosis?

Current findings: CT-OW-02 allocated 106 premenopausal women diagnosed with telogen effluvium, 53 per group.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Diagnostic details, age, baseline hair, causes and applicability to other hair loss, men or postmenopausal women are unverified.
Required materials and conditions: Premenopausal women, diagnosis, eligibility, baseline and exclusions
Materials to obtain first: Eligibility, diagnosis and baseline-characteristic tables
Further research: Distinguish the recruited population from other hair-loss conditions and populations
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Premenopausal women, diagnosis, eligibility, baseline and exclusions; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N03 · What are the actual finished product and study exposure?

Current findings: Exposure to one 25-mL vial/day of the Olistic Women drinkable multi-ingredient nutraceutical for six months is recorded.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: This preserves study identity, not intake guidance or product recommendations. Full ingredients, batches and adherence details are absent from the summary.
Required materials and conditions: Olistic Women finished product, formulation, study exposure and duration
Materials to obtain first: Finished-product, ingredient, batch and study-exposure specifications
Further research: Distinguish finished-product identity from actual exposure and guidance
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Olistic Women finished product, formulation, study exposure and duration; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N04 · Are placebo composition, appearance and blinding verified?

Current findings: The trial was multicenter, double-blind and placebo-controlled; the company supplied product and placebo.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Placebo ingredients, appearance/sensory properties and blinding success/unblinding details are unread. Do not newly certify complete matching.
Required materials and conditions: Product/placebo composition, matching and blinding implementation
Materials to obtain first: Active/placebo specifications and blinding methods
Further research: Distinguish the design name from actual blinding implementation
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Product/placebo composition, matching and blinding implementation; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N05 · Are allocation, analysis, completion and missing-data denominators separated?

Current findings: The original evidence lists 106 randomized (53/53).
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Measured, analyzed, completed and dropout denominators at days 90/180 are absent from the summary. Do not turn 106 allocated into an analysis denominator with all participants completing.
Required materials and conditions: 106 allocated, 53/53, measurements/analysis/exclusions by timepoint
Materials to obtain first: Group flow, analysis and measurement tables by timepoint
Further research: Separate allocation from actually observed and analyzed denominators
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: 106 allocated, 53/53, measurements/analysis/exclusions by timepoint; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N06 · What is the original record scope for random-sequence generation and allocation concealment?

Current findings: The preserved research explanation says random-sequence generation and allocation-concealment methods were not confirmed in the public paper.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: This does not mean the external paper was read now. Do not use parent B1 or the design name as new methods review or allocation certification.
Required materials and conditions: Sequence, concealment, baseline, actual implementation and original descriptions
Materials to obtain first: Original allocation/concealment, baseline and methods material
Further research: Distinguish historically unverified methods from current summary reading
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Sequence, concealment, baseline, actual implementation and original descriptions; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N07 · Are missing-data handling, analysis populations and effects of interest known?

Current findings: The original summary says detailed missing-data handling was not confirmed in the public paper.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not arbitrarily label analysis populations, adjustment, imputation or completer effects. Do not fill gaps with allocation denominators.
Required materials and conditions: Group exclusions, missingness, ITT/PP, models and adjustment
Materials to obtain first: Analysis-population, missing-data, model and sensitivity material
Further research: Separate allocation, actual use, completers and missing-data assumptions
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Group exclusions, missingness, ITT/PP, models and adjustment; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N08 · Can concurrent treatment, changes in hair-loss causes and product adherence be distinguished?

Current findings: The current preserved summary gives a finished-product/placebo comparison and six months.
Verification status: Unverified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Concurrent exposure, changes in disease causes, adherence and between-group deviations are unspecified. Do not claim product contribution was separated from other changes or provide treatment-change methods.
Required materials and conditions: Concurrent treatment, nutrition, other products, causes, changes and adherence
Materials to obtain first: Group tables of concomitant exposure, adherence, changes and baseline causes
Further research: Distinguish finished-product effects from other possible changes
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Concurrent treatment, nutrition, other products, causes, changes and adherence; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N09 · What are the primary endpoint’s measurement, unit and definition?

Current findings: The primary endpoint was change from baseline in hair density measured by TrichoScan phototrichoscopy.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: It differs from appearance, satisfaction and patient perception. Imaging site/area, device, assessors, standardization and repeated-measurement handling details are unread.
Required materials and conditions: TrichoScan phototrichoscopy, change from baseline in density and hairs/cm²
Materials to obtain first: Imaging, measurement, unit and assessment manuals and original tables
Further research: Distinguish device-measured density from patient-centered outcomes
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: TrichoScan phototrichoscopy, change from baseline in density and hairs/cm²; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N10 · Do day-180 changes by group differ from final density?

Current findings: Day-180 change is recorded as product +27.31±2.61 versus placebo +18.23±2.98 hairs/cm².
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not turn changes into final density. The summary does not identify ± as SD or SE; do not calculate baseline/final values or new between-group differences.
Required materials and conditions: Baseline, change and final values for each group and definition of ±
Materials to obtain first: Original group baseline/change/final-value tables and ± definitions
Further research: Distinguish changes, absolute values, dispersion and precision
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Baseline, change and final values for each group and definition of ±; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N11 · What are the test and confidence interval for the selected between-group comparison?

Current findings: The preserved summary gives P<0.01 for the day-180 hair-density comparison and says the 95% CI was not reported.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not create new differences, CIs, relative density or hypothetical examples. Unreported effect intervals must not become confirmed precision.
Required materials and conditions: Day-180 comparison, effect scale, P value and CI
Materials to obtain first: Original between-group effect, test and interval tables
Further research: Display directly reported tests together with gaps in effects/CIs
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Day-180 comparison, effect scale, P value and CI; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N12 · Does an important clinical difference explain the device measurement?

Current findings: The preserved counterview says a clinically important minimum hairs/cm² threshold was not reported.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not invent an important difference, normalized hair fullness or a visible-change criterion.
Required materials and conditions: Prespecified hairs/cm² importance, direct perception and clinical criteria
Materials to obtain first: Prespecified importance criteria and direct appearance/perception results
Further research: Separate statistical values from clinical importance
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Prespecified hairs/cm² importance, direct perception and clinical criteria; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N13 · Was the day-90 result counted as independent replication or merged with day 180?

Current findings: The original description says between-group differences occurred at both days 90 and 180.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Exact day-90 values, P values, CIs and denominators are absent from the summary. Do not count repeat timepoints as new trials/participants or copy day-180 values.
Required materials and conditions: Values, denominators, plans and measurements by timepoint
Materials to obtain first: Day-90/day-180 result and denominator tables
Further research: Distinguish direct timepoint data from shared participants and measurements
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Values, denominators, plans and measurements by timepoint; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N14 · Was the secondary hair-cycle ratio merged with density?

Current findings: The original text gives a prespecified secondary ratio of product 8.20:1→14.19:1 versus placebo 7.43:1→8.76:1, P<0.001.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: This differs from hair density in hairs/cm². Do not convert the ratio to density, individual hair counts or between-group differences or calculate new values.
Required materials and conditions: Anagen-to-catagen/telogen ratio, hierarchy and definition
Materials to obtain first: Secondary-ratio definitions, plans and original tables
Further research: Distinguish density, hair-cycle ratios and analysis hierarchy
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Anagen-to-catagen/telogen ratio, hierarchy and definition; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N15 · Are first registration posting and primary-completion dates distinguished?

Current findings: NCT07111312 was first posted on 2025-08-08; primary completion was 2024-05-10. The original text describes retrospective registration after completion, which cannot support prospective registration.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not newly calculate the date gap or promote retrospective registration to prerecruitment planning.
Required materials and conditions: NCT07111312, first posting, completion, original plans and history
Materials to obtain first: Registration history, prerecruitment plans and completion records
Further research: Display completion, registration and paper events separately
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: NCT07111312, first posting, completion, original plans and history; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N16 · Do original primary/secondary descriptions differ from independently prespecified plans?

Current findings: The preserved summary calls density primary and the hair-cycle ratio a prespecified secondary endpoint while also stating limits of retrospective registration.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Preserve the original hierarchy description without treating it as completed independent prospective verification. Original plans, changes and multiplicity are unread.
Required materials and conditions: Endpoint hierarchy, protocol/SAP, multiplicity and change documents
Materials to obtain first: Protocol/SAP, prerecruitment documents and change history
Further research: Distinguish paper hierarchy descriptions from the verified scope of independent prospective plans
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Endpoint hierarchy, protocol/SAP, multiplicity and change documents; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N17 · Does TrichoScan density mean visibly fuller hair?

Current findings: The original text distinguishes TrichoScan hair counts from a patient judging hair to look fuller. The separate appearance subclaim has grade ?.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not fill appearance, perception, satisfaction or treatment success with a positive density result or newly change that subclaim assessment.
Required materials and conditions: Direct appearance, satisfaction, perception and function endpoints
Materials to obtain first: Direct patient-centered appearance, satisfaction and function material
Further research: Distinguish device measurements from gaps in the separate appearance question
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Direct appearance, satisfaction, perception and function endpoints; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N18 · Was a finished-product effect extended to ingredients or other hair supplements?

Current findings: The original advertising interpretation says ingredients, formulations and populations vary by product, so Olistic results cannot become effects of Viviscal, Nutrafol or all hair supplements.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not create ingredient-specific benefits, product equivalence or recommendations for other brands. Full original ingredient specifications are also absent from the summary.
Required materials and conditions: Direct comparisons for this product, other formulations and individual ingredients
Materials to obtain first: Direct comparisons by finished product, formulation and ingredient
Further research: Preserve applicability boundaries between this product and other product/ingredient questions
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Direct comparisons for this product, other formulations and individual ingredients; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N19 · Does six-month efficacy mean persistence after completion or prevention of all hair loss?

Current findings: The original trial lasted six months/180 days; the original counterpoint says it does not establish durability or effects of other formulations.
Verification status: Unverified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not fill postcompletion persistence, disease prevention, treatment of all hair loss or treatment substitution with numbers.
Required materials and conditions: Postcompletion follow-up, long-term density and clinical outcomes
Materials to obtain first: Postcompletion density and clinical-outcome follow-up
Further research: Distinguish exposure-period results from direct postcompletion results
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Postcompletion follow-up, long-term density and clinical outcomes; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N20 · Are the same trial, citation, registration and two subclaims independent replication?

Current findings: The original material links one trial in 106 people, one citation and NCT07111312. Density, hair-cycle ratios, days 90/180 and the appearance sibling row share the same report context.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not count the paper, registration, timepoints, two groups or sibling sheets as new independent trials/participants. Confirmed trial/participant counts remain unrecorded.
Required materials and conditions: CT-OW-02, paper, registration, shared participants and timepoint linkage
Materials to obtain first: Report, registration, measurement and participant-linkage material
Further research: Distinguish endpoint/report slots from trial/participant units
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: CT-OW-02, paper, registration, shared participants and timepoint linkage; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N21 · Is there independent replication beyond one small manufacturer trial?

Current findings: The original rationale describes one trial in 106 people (53/53), the limitation of fewer than 200 participants and manufacturer-only evidence.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not turn the 200-person statement into an arbitrary passing sample size or new importance criterion. Do not newly certify independent replication or applicability to other conditions.
Required materials and conditions: Actual independent replication of the same finished product, population and duration
Materials to obtain first: Direct replication/applicability material for the same question
Further research: Distinguish original sample-size limits from gaps in independent replication
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Actual independent replication of the same finished product, population and duration; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N22 · Are research funding, publication fees and product/placebo support separated?

Current findings: The original text says Olistic Research Labs S.L. fully funded research and publication fees and supplied product and placebo.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not turn manufacturer support into public or independent support. Specific contracts, batches and other roles are unread.
Required materials and conditions: Company funding, publication fees and product/placebo supply disclosures
Materials to obtain first: Funding, publication-fee and product/placebo disclosures and contracts
Further research: Display research costs, publication fees and product support separately
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Company funding, publication fees and product/placebo supply disclosures; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N23 · Are sponsor, responsible party and company-employed author distinguished?

Current findings: The original text says the company was sponsor/responsible party and Manuel Sáez Moya was affiliated with the company.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not turn responsibility or employee authorship into independent operations. Full individual contributions, data control and publication authority are unverified.
Required materials and conditions: Responsibility, registrant, author relationships/contributions and data rights
Materials to obtain first: Registrant, author COI, contribution and authority disclosures
Further research: Distinguish support, responsibility, employees and individual roles
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Responsibility, registrant, author relationships/contributions and data rights; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N24 · Were all outsourced analysis, medical writing and editing roles verified?

Current findings: Research/publication costs, product/placebo supply and some responsibility/affiliation information are preserved.
Verification status: Unverified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not certify unmentioned outsourced analysis, medical writing, editing or other roles as absent or fully independent.
Required materials and conditions: Actual disclosures of analysis, writing, editing and other support
Materials to obtain first: Full support, analysis, writing, data and publication-role disclosures
Further research: Record reported involvement separately from unverified roles
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Actual disclosures of analysis, writing, editing and other support; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N25 · Are noncollection and nonreporting of minor adverse events distinguished?

Current findings: The original research explanation and safety detail explicitly say minor adverse events were not collected at all.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not turn noncollection into zero events, no problems or good general tolerability. Parent safety Unknown is the original record.
Required materials and conditions: Harm collection/classification, group observations and exposure denominators
Materials to obtain first: Full harm-collection scope, group events and exposure tables
Further research: Distinguish noncollection from observed zero events and nonreporting
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Harm collection/classification, group observations and exposure denominators; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N26 · Are serious-harm, discontinuation and relatedness material available?

Current findings: The summary explicitly states minor adverse events were not collected and this trial alone cannot establish safety.
Verification status: Unverified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Full serious-event tables, group denominators, relatedness and discontinuation material are absent from the summary; do not create absence or safety equivalence.
Required materials and conditions: Serious events, discontinuation/reasons, relatedness, control and denominators
Materials to obtain first: Serious-event, discontinuation, relatedness and group-denominator material
Further research: Display collection limits separately from gaps in other harm material
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Serious events, discontinuation/reasons, relatedness, control and denominators; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N27 · Can long-term/rare harms or tolerability in other populations be judged?

Current findings: The original trial lasted six months and harm collection was incomplete.
Verification status: Unverified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Do not fill absence of long-term/rare harms, safety in other sexes/hair-loss conditions/ages or general tolerability.
Required materials and conditions: Long exposure, rare events, vulnerable populations and follow-up
Materials to obtain first: Long-term/rare-event and population-specific exposure/harm material
Further research: Distinguish short-term efficacy values from gaps in long-term safety
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Long exposure, rare events, vulnerable populations and follow-up; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Supplementary condition exposing harm-collection, denominator and follow-up limits separately from efficacy
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N28 · Are the actually read summary and external abstract/full text/registration/plans shown?

Current findings: The full preserved summary was actually read; the PubMed URL is linked as an original bibliographic reference.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: External abstracts, full texts, registration, protocol/SAP, links and screens were not checked. Do not turn URL presence or historical original-text descriptions into new external reading or content review.
Required materials and conditions: Preserved summary, citation URL and actual reading status by material
Materials to obtain first: Original paper, registration and protocol/SAP
Further research: Display summary reading and unread external material separately
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Preserved summary, citation URL and actual reading status by material; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01

N29 · Are original history, parent values and linkage separated from production and review of existing content?

Current findings: Preserve Korean/English text, axes, the 2026-08-26 evidence date, empty correction/deliberation records and subclaims in the full original summary. Existing review-pending/production-eligibility indicators are historical.
Verification status: Partly verified
Materials actually read: Summary read; related external material unread
Why unverified: Display preserved-summary information, scope and direct gaps in production; this is not completed content review or a new clinical assessment
Reason for missing information: Retain absent subclaim scores/status/axes; the evidence date is not a current review date. The existing review wait is not activated, content review remains incomplete, completion is false, new units are zero and final independent counts are unrecorded.
Required materials and conditions: Korean/English text, axes, dates, corrections, existing selection and freeze/application
Materials to obtain first: Original preserved summary, existing selection and freeze/application production events
Further research: Record original assessment/corrections separately from production and review of existing content
Remaining uncertainty: External abstract, full text, registration, protocol and SAP unread; no new calculation, content review or clinical checks
Conditions for verification: Korean/English text, axes, dates, corrections, existing selection and freeze/application; preserve original values, direct observations, scope and gaps without creating new effects, assessments, calculations or independent certification
Why this condition is needed: Production condition exposing direct original material, formulation, comparison, denominators and gaps for the selected endpoint
Application exceptions: Do not fill unverified selected material with other endpoints, formulations, trials or person/eye/measurement units
Referenced methods: Retain the production copy of existing methodology application records and methodology linkage; full definition review and official certification are incomplete

Related sources R01